Filing Details

Accession Number:
0001181431-15-007558
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-05-27 18:39:20
Reporting Period:
2015-05-26
Filing Date:
2015-05-27
Accepted Time:
2015-05-27 18:39:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1501756 Avalanche Biotechnologies Inc. [AAVL] Biological Products, (No Disgnostic Substances) (2836) 205258327
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1504491 Paul Wachter C/O Avalanche Biotechnologies, Inc.
1035 O'Brien Drive, Suite A
Menlo Park CA 94025
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2015-05-26 786 $36.52 41,143 No 4 S Indirect See Footnote
Common Stock Disposition 2015-05-26 304 $37.59 40,839 No 4 S Indirect See Footnote
Common Stock Disposition 2015-05-26 102 $38.30 40,737 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 2,000 Direct
Footnotes
  1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
  2. This transaction was executed in multiple trades in prices ranging from $36.020 to $37.020, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. The shares are held directly by the Wachter Family Trust.
  4. This transaction was executed in multiple trades in prices ranging from $37.025 to $38.020, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  5. This transaction was executed in multiple trades in prices ranging from $38.050 to $38.620, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.